Kaken Pharmaceutical Co (KKPCF) Stock Statistics & Valuation Metrics

Kaken Pharmaceutical Co has a market cap or net worth of $873.90M. The enterprise value is $91.72B.

Market Cap

$873.90M

Enterprise Value

$91.72B

Kaken Pharmaceutical Co has 44,139,730 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

44,139,730

Owned by Insiders

―

Owned by Institutions

7.95%

Kaken Pharmaceutical Co’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is -0.52%.

Return on Equity (ROE)

0.01

Return on Assets (ROA)

0.01

Return on Invested Capital (ROIC)

-0.52%

Return on Capital Employed (ROCE)

-0.01

Revenue Per Employee

69.00M

Profits Per Employee

1.92M

Employee Count

1,114

Asset Turnover

0.43

Inventory Turnover

1.97

The current PE Ratio of Kaken Pharmaceutical Co is 14.07. Kaken Pharmaceutical Co’s PEG ratio is -0.03.

PE Ratio

14.07

PS Ratio

1.65

PB Ratio

0.95

Price to FCF

0.00

Price to Operating Cash Flow

0.00

PEG Ratio

-0.03

In the last 12 months, Kaken Pharmaceutical Co had revenue of 76.87B and earned 2.14B in profits. Earnings per share was 56.55.

Revenue

76.87B

Gross Profit

39.24B

Operating Income

-899.00M

Pretax Income

2.31B

Net Income

2.14B

EBITDA

5.68B

Earnings Per Share (EPS)

56.55

In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.

Operating Cash Flow

0

Free Cash Flow

0

Free Cash Flow per Share

0.00

Kaken Pharmaceutical Co pays an annual dividend of $0.58, resulting in a dividend yield of 4.85%

Dividend Per Share

$0.58

Dividend Yield

4.85%

Payout Ratio

N/A

Free Cash Flow Yield

0.00%

Earnings Yield

7.11%

Beta

0.08

52-Week Price Change

3.08%

50-Day Moving Average

24.80

200-Day Moving Average

25.07

Relative Strength Index (RSI)

51.15

Average Volume (3m)

―

Kaken Pharmaceutical Co upcoming earnings date is Nov 09, 2026, TBA (Not Confirmed).

Last Earnings Date

Aug 07, 2026

Next Earnings Date

Nov 09, 2026

Ex-Dividend Date

Sep 29, 2026

Kaken Pharmaceutical Co as a current ratio of 4.52, with Debt / Equity ratio of 2.61%

Current Ratio

4.52

Quick Ratio

3.60

Debt to Market Cap

0.02

Net Debt to EBITDA

-7.19

Interest Coverage Ratio

-19.98

In the past 12 months, Kaken Pharmaceutical Co has paid 168.00M in taxes.

Income Tax

168.00M

Effective Tax Rate

0.07

Kaken Pharmaceutical Co EV to EBITDA ratio is 5.51, with an EV/FCF ratio of 0.00.

EV to Sales

1.03

EV to EBITDA

5.51

EV to Free Cash Flow

0.00

EV to Operating Cash Flow

0.00

Kaken Pharmaceutical Co has $55.40B in cash and marketable securities with $3.85B in debt, giving a net cash position of $51.55B billion.

Cash & Marketable Securities

$55.40B

Total Debt

$3.85B

Net Cash

$51.55B

Net Cash Per Share

$1,167.95

Tangible Book Value Per Share

$3,368.37

Gross margin is 57.95%, with operating margin of 11.33%, and net profit margin of 11.70%.

Gross Margin

57.95%

Operating Margin

11.33%

Pretax Margin

14.91%

Net Profit Margin

11.70%

EBITDA Margin

18.75%

EBIT Margin

14.57%

The average price target for Kaken Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

-9.95%

EPS Growth Forecast

-22.40%